FHD-286 in Subjects With Advanced Hematologic Malignancies

FHD-286 in Subjects With Advanced Hematologic Malignancies
Conditions:   Advanced Hematologic Malignancy;   Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Relapsed Myelodysplastic Syndromes;   Refractory Myelodysplastic Syndromes
Intervention:   Drug: FHD-286
Sponsors:   Foghorn Therapeutics Inc.;   Syneos Health

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 19, 2021Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine